Shares of Intersect ENT (NASDAQ:XENT) were unchanged at $13.49 after the company reported Q1 results.
Earnings per share decreased 54.29% year over year to ($0.54), which missed the estimate of ($0.44).
Revenue of $19,826,000 lower by 25.67% year over year, which missed the estimate of $23,660,000.
Earnings guidance hasn't been issued by the company for now.
Intersect ENT hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 11, 2020
Time: 07:04 PM ET
52-week high: $31.46
Company's 52-week low was at $5.97
Price action over last quarter: down 42.84%
Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.